Altimmune Inc reports results for the quarter ended June 30 - Earnings Summary

Altimmune

12/08/2026 14:31

Altimmune Inc ALT.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -27 cents.  The mean expectation of ten analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -21 cents to -10 cents per share.
Reported revenue was zero​; analysts expected zero. 
Altimmune Inc's reported EPS for the quarter was a loss of 12 cents​.
The company reported a quarterly loss of $23.64 million.
Altimmune Inc shares had fallen by 1.3% this quarter and lost 16.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 27.7% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Altimmune Inc is $19.00, about 84.2% above its last closing price of $3.00
This summary was machine generated from LSEG data August 12 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.14
-0.12
Beat
Mar. 31 2026 
-0.25
-0.18
Beat
Dec. 31 2025 
-0.24
-0.27
Missed
Sep. 30 2025 
-0.28
-0.21
Beat